参考文献/References:
[1] Alotaibi H, Tuzlako?lu-Öztörk M, Tazebay UH.The thyroid Na+/I- symporter:molecular characterization and genomic regulation[J]. Mol Imaging Radionucl Ther, 2017, 26(Suppl 1):S92-101. DOI:10.4274/2017.26.suppl.11.
[2] Portulano C, Paroder-Belenitsky M, Carrasco N. The Na+/I- symporter (NIS):mechanism and medical impact[J]. Endocr Rev, 2014, 35(1):106-149. DOI:10.1210/er.2012-1036.
[3] Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer[J]. Nat Med, 2000, 6(8):871. DOI:10.1038/78630.
[4] Bakheet SM, Hammami MM. Patterns of radioiodine uptake by the lactating breast[J]. Eur J Nucl Med, 1994, 21(7):604-608. DOI:10. 1007/BF00285581.
[5] 贾莉, 夏正武, 马世兴, 等. 分化型甲状腺癌131I治疗后假阳性显像分析[J].中国医学创新, 2011, 8(31):144-145. Jia L, Xia ZW, Ma SX, et al. Analysis of false positive imaging 131I after treatment of differentiated thyroid carcinoma[J]. Med Innov Chin, 2011, 8(31):144-145.
[6] Hammami MM, Bakheet S. Radioiodine breast uptake in nonbreastfeeding women:clinical and scintigraphic characteristics[J]. J Nucl Med, 1996, 37(1):26-31.
[7] Wilson LM, Barrington SF, Morrison ID, et al. Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma[J]. Eur J Nucl Med, 1998, 25(6):622-628.
[8] Vermiglio F, Baudin E, Travagli JP, et al. Iodine concentration by the thymus in thyroid carcinoma[J]. J Nucl Med, 1996, 37(11):1830-1831.
[9] 王叙馥, 张勤, 刘新峰, 等. 分化型甲状腺癌术后胸腺浓聚131I的临床分析[J]. 标记免疫分析与临床, 2014, 21(5):525-527, 531. DOI:10.11748/bjmy.issn.1006-1703.2014.05.009. Wang XF, Zhang Q, Liu XF, et al. Clinical analysis of thymic concentrated 131I in differentiated thyroid carcinoma after operation[J]. Labeled Immunoassay Clin Med, 2014, 21(5):525-527, 531.
[10] Michigishi T, Mizukami Y, Shuke N, et al. Visualization of the thymus with therapeutic doses of radioiodine in patients with thyroid cancer[J]. Eur J Nucl Med, 1993, 20(1):75-79.
[11] 李永军, 徐兆强, 柳卫, 等. 分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J]. 国际放射医学核医学杂志, 2014, 38(4):227-231. DOI:10.3760/cma.j.issn.1673-4114. 2014. 04.005. Li YJ, Xu ZQ, Liu W, et al. Clinical research on physiological thymic uptake of 131I in post -operative patients with differentiated thyroid cancer[J]. Int J Radiat Med Nucl Med, 2014, 38(4):227-231.
[12] Kienast O, Hofmann M, Ozer S, et al. Retention of iodine-131 in respiratory tract in a patient with papillary thyroid carcinoma after radionuclide therapy:a rare false-positive finding[J]. Thyroid, 2003, 13(5):509-510. DOI:10.1089/105072503322021197.
[13] Bakheet S, Hammami MM. False-positive thyroid cancer metastasis on whole-body radioiodine scanning due to retained radioactivity in the oesophagus[J]. Eur J Nucl Med,1993, 20(5):415-419.
[14] 陈可靖. 甲状腺癌131I显像假阳性的分析及鉴别诊断[J]. 国际放射医学核医学杂志, 2000, 24(1):11-14. Chen KJ. The analysis and differentiate diagnosis of false positive 131I imaging in metastatic thyroid carcinoma[J]. Int J Radiat Med Nucl Med, 2000, 24(1):11-14.
[15] Ceylan GE, Erdogan A. Mediastinal radioiodine uptake due to hiatal hernia:a false-positive reason in 131I scan[J]. Rev Esp Med Nucl, 2010, 29(2):95. DOI:10.1016/j.remn.2009.11.007.
[16] Mena Bares LM, vallejo Casas JA, Moreno Orteqa E, et al. I -131 visualization of thoracic aortic aneurysm after radioiodine administration for thyroid carcinoma[J]. Clin Nucl Med, 2008, 33(8):553-554. DOI:10.1097/RLU.0b013e31817deb95.
[17] Ranade R, Pawar S, Mahajan A, et al. Unusual false positive radioiodine uptake on (131)I whole body scintigraphy in three unrelated organs with different pathologies in patients of differentiated thyroid carcinoma:a case series[J]. World J Nucl Med, 2016, 15(2):137-141. DOI:10.4103/1450-1147.176884.
[18] Kayano D, Michigishi T, Kenji I, et al. 131I uptake in a thymic cyst[J]. Clin Nucl Med, 2010, 35(6):438-439. DOI:10.1097/RLU. 0b013e3181db4d21.
[19] Malhotra G, Moghe SH, Ranade R, et al. An unusual False-Positive uptake of radioiodine in pericardial effusion on posttherapy scan[J]. Clin Nucl Med, 2016, 41(7):568-569. DOI:10.1097/RLU.0000000000001223.
[20] 罗全勇, 陈立波, 余永利, 等. 分化型甲状腺癌131I治疗后扫描的假阳性分析[J].中国医学影像技术, 2004, 20(12):1930-1932. DOI:10.3969/j.issn.1674-4985.2011.31.081. Luo QY, Chen LB, Yu YL, et al. False-positive analysis of 131I scan in differentiated thyroid carcinoma[J]. Chin J Med Imaging Technol, 2004, 20(12):1930-1932.
[21] Muldoon EG, Sharman A, Page I, et al. Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis[J]. BMC Pulm Med, 2016, 16(1):123. DOI:10.1186/s12890-016-0276-3.
[22] Thientunyakit T. False-positive 131I whole-body scan in well-differentiated thyroid cancer patient with respiratory bronchiolitis[J]. Clin Nucl Med, 2013, 38(9):730-734. DOI:10.1097/RLU. 0b013e318286bbfa.
[23] H觟schl R, Choy DH, Gandevia B. Iodine-131 uptake in inflammatory lung disease:a potential pitfall in treatment of thyroid carcinoma[J]. J Nucl Med,1988, 29(5):701-706.
[24] Triggiani V, Moschetta M, Giagulli VA, et al. Diffuse 131I lung uptake in bronchiectasis:a potential pitfall in the follow -up of differentiated thyroid carcinoma[J]. Thyroid, 2012, 22(12):1287-1290. DOI:10. 1089/thy.2011.0439.
[25] Esp侏rito Santo R, Marques P, Jo觔o Bugalho M. False-positive uptake on radioiodine whole-body scan due to bronchiectasis[J/OL]. BMJ Case Rep, 2015, 2015:pii:bcr2015213169[2017-07-02] . https://www.ncbi.nlm.nih.gov/pubmed/26561230. DOI:10.1136/bcr-2015-213169.
[26] Triggiani V, Giagulli VA, Iovino M, et al. False positive diagnosis on (131)Iodine whole-body scintigraphy of differentiated thyroid cancers[J]. Endocrine, 2016, 53(3):626-635. DOI:10.1007/s12020-015-0750-3.
[27] Garger YB, Winfeld M, F riedman K, et al. In thyroidectomized thyroid cancer patients, false-positive I-131 whole body scans are often caused by inflammation rather than thyroid cancer[J/OL].J Investigative Med High Impact Case Reports, 2016, 4(1):23247096-16633715[2017-07-02] . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776247/.DOI:10.1177/2324709616633715.
[28] Nauseef WM. Myeloperoxidase in human neutrophil host defence[J]. Cell Microbiol, 2014, 16(8):1146-1155. DOI:10.1111/cmi.12312.
[29] Regalbuto C, Buscema M, Arena S, et al. False-positive findings on (131)I whole-body scans because of posttraumatic superficial scabs[J].J Nucl Med, 2002, 43(2):207-209.
[30] Brucker-Davis F, Reynolds JC, Skarulis MC, et al. False-positive iodine -131 whole -body scans due to cholecystitis and sebaceouscyst[J]. J Nucl Med, 1996, 37(10):1690-1693.
[31] Dreyfuss F, Ben-porath M, Menczel J. Radioiodine uptake by the infarcted heart[J]. Am J Cardiol, 1960, 6(2):237-245. DOI:10.1016/0002-9149(60)90310-6.
[32] Oh JR, Ahn BC. False-positive uptake on radioiodine whole-body scintigraphy:physiologic and pathologic variants unrelated to thyroid cancer[J/OL]. Am J Nucl Med Mol Imaging, 2012, 2(3):362-385[2017-07-02] . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477738/.
[33] Wapnir IL, Goris M, Yudd A, et al. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid[J]. Clin Cancer Res, 2004,10(13):4294-4302.DOI:10.1158/1078-0432.CCR-04-0074.
[34] Wapnir IL, Van De Rijn M, Nowels K, et al. Immunohistochemical profile of the Sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections[J]. J Clin Endocrinol Metab, 2003, 88(4):1880-1888. DOI:10.1210/jc.2002-021544.
[35] Haubold-Reuter BG, Landolt U, von Schulthess GK. Bronchogenic carcinoma mimicking metastatic thyroid carcinoma[J]. J Nucl Med, 1993, 34(5):809-811.
[36] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203):436-444. DOI:10.1038/nature07205.
[37] Berger F, Unterholzner S, Diebold J, et al. Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma[J]. Biochem Biophys Res Commun, 2006, 349(4):1258-1263. DOI:10.1016/j.bbrc.2006.08.170.
[38] De Keizer B, Arsos G, Smit JW, et al. I-131 accumulation in a benign cystic mesothelioma in a patient with follicular thyroid cancer[J]. Thyroid, 2008, 18(3):369-371.DOI:10.1089/thy.2007.0155.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[12]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[13]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[14]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[15]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[16]李永军,徐兆强,柳卫,等.分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J].国际放射医学核医学杂志,2014,38(4):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
Li Yongjun,Xu Zhaoqiang,Liu Wei,et al.Clinical research on physiological thymic uptake of 131I in post-operative patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
[17]张璐,詹维伟,张一帆.颈部超声在分化型甲状腺癌131I治疗中的应用进展[J].国际放射医学核医学杂志,2014,38(4):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
Zhang Lu,Zhan Weiwei,Zhang Yifan.Application of neck ultrasonography in 131I radiotherapy of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
[18]汤敏敏,刘建中,武志芳,等.分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J].国际放射医学核医学杂志,2014,38(6):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
Tang Min-min,Liu Jian-zhong,Wu Zhi-fang,et al.Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
[19]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[20]易艳玲,石洪成,顾宇参,等.分化型甲状腺癌患者日尿排泄131I活度分数估算[J].国际放射医学核医学杂志,2010,34(4):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
YI Yah-ling,SHI Hong-cheng,GU Yu-shen,et al.Estimation the daily urinary excretion 131I radioactivity of patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]